| Name | Title | Contact Details |
|---|
ANX Home Healthcare provides physician-ordered skilled nursing and health care services to homebound patients recovering from illness or injury. We have worked with physicians and families in developing custom home care solutions for patients requiring specialists in: • Wound care • Diabetes management • Cardiac rehabilitation • Physical therapy • Occupational therapy • Speech therapy • Nutritional assessments • Dietary counseling Our services are provided by a highly skilled interdisciplinary team of experts with over 75 years of combined experience in the health care industry. We pride ourselves in our ability to quickly respond to physician and clinician requests for patient home care. Best of all, you can count on us to provide service 24/7. With a team of full-time clinicians, we are able to initiate start of care within 24 hours. Established by Thomas Allandale Rocas III (RN, BSN, Certified Wound Care Specialist) and Lisa Mangubat (RN, BSN) in August 2007 with a vision of client-focused quality care and service for home-bound patients, ANX Home Healthcare is now in our ninth year of practice in the San Francisco Bay Area. We remain committed to providing competent and reliable care utilizing cutting-edge technology.
Kiosk Group Inc is a Knoxville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Omrix Biopharmeceuticals, Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baird Nursing Home is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.